Guidewave Ltd was established in 2015 as a subsidiary of Diasolve Ltd, with the specific purpose of commercialising innovative products to enable intracoronary infusion in the cath lab and so improve the FFR procedure and make possible further novel diagnostic and interventional procedures. The products and underpinning technologies have been developed by Diasolve with the support of a Phase 2 SBRI Stratified Medicine award from Innovate UK. Diasolve’s lead product, an FFR Infusion Microcatheter, has been developed within a ISO 13485 compliant quality system and has recently entered clinical investigation in the UK (www.hyperemicstudy.com).
Guidewave is led by Paul Weinberger, Managing Director and Diasolve’s board representative. The other directors are Graham Gutsell (founder of GSG Technology) responsible for product engineering and Dr Ahmed Elghamaz, consultant cardiologist at North West London NHS Trust and an advisor to Diasolve. The company is headquartered at the London Bioscience Innovation Centre and makes use of resources at Diasolve in Salisbury and GSG Technology in Cambridge.
Guidewave Ltd is led by Paul Weinberger, Managing Director and Diasolve’s board representative. Paul founded Diasolve in 2010, bringing 25 years of expertise in the IVD, Medical Device and Pharmaceutical industries. He has extensive experience of starting and growing companies, having founded Diasolve Ltd and Guidewave Ltd, and worked as CMO for Lumora Ltd (now ERBA MDX) and Director of Clinical Development at Enigma Diagnostics where he led the early development of the ML PCR system. Earlier experience included 10 years with Roche Diagnostics and five with The Wellcome Foundation (now GSK). In other business related activities Paul has spent six years as a founding member of the NICE Diagnostics Advisory Committee, and is currently a member of the BIVDA board. He has an MBA from London Business School and a first degree in pharmacology.
Ahmed Elghamaz graduated from Cairo University medical school in 1997 and did all his post-graduate training in the UK. He became a consultant interventional cardiologist in 2010 and has since led the interventional cardiac research in Northwick Park Hospital, London North West NHS Trust. He is the PI of numerous multi-national trials and has become the lead contributor in several studies. He has a special interest in myocardial perfusion, coronary flow reserve and the functional assessment of coronary artery stenosis. He has worked closely with Diasolve and Guidewave in researching and developing new technologies to enable a better and easier assessment of fractional flow reserve. He has many publications and abstracts within the field in peer journals.
Graham Gutsell is a founding Director of Guidewave. He is a chartered mechanical engineer with over 30 years experience of technology innovation and product development, the majority of which has focussed on medical/IVD devices. He helped to oversee the development of Diasolve’s HyperemIC microcatheter and has been a driving force behind the company’s future products featured on this website. Graham runs his own consulting company, GSG Technology Ltd from its facilities in Cambridge, and has supported a number of other early stage ventures in the sector. Prior to forming his own company, Graham spent many years with TTP plc, a leading technology consultancy based in Cambridge, UK.